Keyword: Ireland

Sublimity Therapeutics hired Jesse Hall as chief medical officer, as it looks to move its lead candidate into a phase 2b ulcerative colitis study.

Neurent Medical raised nearly $11 million in a series A round to commercialize its in-office treatment for persistent runny nose linked to rhinitis.

Icon has hired a retired colonel who is moving into the biotech sphere as new president of its subsidiary ClinicalRM.

We look at a selection of biopharma stories from across Europe this week.

GE is setting up a new site, to be known as “GE BioPark Cork,” as it looks to boost its off-the-shelf biomanufacturing facilities in Ireland.

Ireland’s Horizon Pharma will pay a 21% premium for California-based Raptor Pharmaceutical as it looks to bolster its rare disease portfolio while also expanding its geographical footprint--but it will also gain a tough pipeline that has been hit by failures over the past year.

The privately owned Dublin, Ireland-based DS Biopharma has spun out a company from its ranks in order for it to focus specifically on scarring diseases, while the parent firm will move on with dermatology candidates.

The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal was to go ahead.